ABSTRACT
Gout is the second largest metabolic disease in China， which can cause joint tissue damage and a variety of chronic diseases， and seriously affect human life and health. The increase in uric acid caused by disorder of purine metabolism or abnormal uric acid excretion is the biochemical basis of its pathogenesis. Western medical treatment mainly uses anti-inflammatory drugs such as colchicine， non-steroidal anti-inflammatory drugs， and uric acid lowering drugs such as febuxostat and benzbromarone， which have obvious effects， but there are problems such as easy to recurrence after drug withdrawal and more adverse reactions. Traditional Chinese medicine （TCM） has a long history in the treatment of gout， and has the advantages of multi-channel， multi-target， and multi-level symptomatic treatment. It exerts therapeutic effects through lowering uric acid， anti-inflammatory， anti-oxidation， and protecting the kidneys. Its curative effect is obvious and the adverse reaction rate is low. In recent years， there have been many studies on the mechanism of TCM for gout animal models. Based on the review of relevant literature in recent years， this article has systematically sorted out the pathogenesis of gout， the mechanism of TCM for gout and related experimental design. The paper summarized and analyzed the mechanism of TCM in the treatment of gout from the aspects of regulating the level of inflammatory factors， inhibiting oxidation reaction， reducing uric acid and regulating signaling pathway， so as to provide reference for the research and development of drugs for gout.
ABSTRACT
Literatures on pain intervention with transcutaneous electrical acupoint stimulation (TEAS) were collected by searching the databases both in Chinese and English, and summarized to understand the research progress of TEAS effects on pain mediators in recent years. This will provide a more objective and scientific theoretical basis for clinical practice of TEAS to treat pain syndrome, thus promoting the clinical application of TEAS. Our literature analysis indicated that TEAS effectively regulated the release levels of various pain factors such as prostaglandin, 5-hydroxytryptamine, interleukins, substance P and tumor necrosis factor-α to achieve the analgesic effects by affecting the conduction pathways. TEAS is a safe, non-invasive and effective treatment for pain syndrome. However, further research is necessary due to the lack of rigor of the current clinical trial design.
ABSTRACT
OBJECTIVE@#To observe the therapeutic effect between acupuncture combined with medication and simple medication on migraine and cerebral hemodynamics.@*METHODS@#A total of 120 patients with migraine were randomized into an acupuncture plus medication group (60 cases, 3 cases dropped off) and a medication group (60 cases, 6 cases dropped off). In the medication group, flunarizine hydrochloride capsule was given orally before sleep, 10 mg a day. On the basis of the treatment in the medication group, acupuncture was applied at Sizhukong (TE 23), Shuaigu (GB 8), Taiyang (EX-HN 5), Fengchi (GB 20) and etc. in the acupuncture plus medication group, 30 min each time, once a day. Treatment for 4 weeks was required in both groups. Before and after treatment, the visual analogue scale (VAS) score, indexes of cerebral hemodynamic [blood flow velocity of anterior cerebral artery (ACA), middle cerebral artery (MCA), posterior cerebral artery (PCA), vertebral artery (VA) and basilar artery (BA)] and total TCM syndrome score were observed, and the clinical therapeutic effect and the incidence of the adverse events were evaluated in both groups.@*RESULTS@#Compared before treatment, the VAS scores, the blood flow velocity of ACA, MCA, PCA, VA, BA and the total TCM syndrome scores were decreased in both groups (@*CONCLUSION@#Acupuncture combined with flunarizine hydrochloride capsule can effectively relieve the pain in patients with migraine, reduce the cerebral blood flow velocity, the efficacy is superior to simple flunarizine hydrochloride capsule.
Subject(s)
Humans , Acupuncture Points , Acupuncture Therapy , Hemodynamics , Migraine Disorders/therapy , Pain , Treatment OutcomeABSTRACT
<p><b>OBJECTIVE</b>The reduced expression or expression deletion of LIM domain-containing protein 1(LIMD1) gene associates with the occurrence of various solid tumors, while its role in adult acute leukemia (AL) has been rarely reported, this study was to detect LIMD1 expression in adult patients with AL and to evaluate its correlation with the different clinical and laboratorial data.</p><p><b>METHODS</b>The expression levels of LIMD1 were determined by real-time quantitative PCR (RT-qPCR), LIMD1 transcripts were measured by using a relative quantification with GAPDH as a housekeeping gene, and the relationship between its expression levels and clinical parameters (sex, age, subtype, leukocyte count, leukemic blasts) was investigated by statistical analysis.</p><p><b>RESULTS</b>The LIMD1 expression was reduced in de novo AL patients as compared with normal controls and complete remission patients(P < 0.01). In univariate analysis, LIMD1 associated with age and leukocyte count (P = 0.011, 0.035 respectively). LIMD1 decreased along with increasing age and leukocyte count in de novo AL patients, the LIMD1 expression levels in de novo AL patients with age ≥ 60 years old were lower than that in group of patients <60 years, and which were significantly lower in the leukocyte count ≥ 100×10(9)/L compared to leukocyte count < 100×10(9)/L. there was no statistically significant association between LIMD1 expression and sex, subtype, and leukemic blasts of patients.</p><p><b>CONCLUSIONS</b>The LIMD1 gene may be involved in the pathogenesis and progression of adult AL, and may be used as an indicator of prognosis evaluation.</p>
Subject(s)
Adult , Humans , Middle Aged , Acute Disease , Disease Progression , Gene Expression Regulation, Neoplastic , Intracellular Signaling Peptides and Proteins , LIM Domain Proteins , Leukemia , PrognosisABSTRACT
<p><b>OBJECTIVE</b>To explore the expression of insulin-like growth factor binding protein 3 (IGFBP3) in acute myeloid leukemia and its clinical significance.</p><p><b>METHODS</b>Using GAPDH as internal reference, IGFBP3 gene expression was detected in the bone marrow mononuclear cells of 43 de novo AML patients, 36 patients with complete remission (CR) and 28 cases of controls by using SYBR-Green I real-time quantitative PCR, the differences of gene expression between the three groups were compared.</p><p><b>RESULTS</b>IGFBP3 gene expression level in the de novo group were lower than that in CR group and control group (P < 0.05), but there was no statistically significant difference of IGFBP3 expression level in CR group and control group (P > 0.05).</p><p><b>CONCLUSIONS</b>The IGFBP3 as a tumor suppressor gene may play a role in the pathogenesis of acute myeloid leukemia, its expression level is recovered after complete remission, therefore, IGFBP3 can be used as an indicator of evaluating clinical curative effect.</p>